Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-04-20
2011-12-27
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S178100, C424S180100, C424S181100, C424S183100
Reexamination Certificate
active
08084029
ABSTRACT:
The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4331647 (1982-05-01), Goldenberg
patent: 4704692 (1987-11-01), Ladner
patent: 4824659 (1989-04-01), Hawthorne
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5011771 (1991-04-01), Bellet et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5229275 (1993-07-01), Goroff
patent: 5443953 (1995-08-01), Hansen et al.
patent: 5567610 (1996-10-01), Borrebaeck et al.
patent: 5612016 (1997-03-01), Griffiths
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5716595 (1998-02-01), Goldenberg
patent: 5753206 (1998-05-01), McBride et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6254868 (2001-07-01), Leung et al.
patent: 6331175 (2001-12-01), Goldenberg
patent: 6761876 (2004-07-01), Serbedzija et al.
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: 94/22490 (1994-10-01), None
patent: 96/37516 (1996-11-01), None
patent: 98/44001 (1998-10-01), None
patent: 00/29584 (2000-05-01), None
patent: 00/63403 (2000-10-01), None
patent: 01/00245 (2001-01-01), None
patent: 02/07783 (2002-01-01), None
Amato et al., “Radioimmunodetection of residual, recurrent or metastatic germ cell tumors using technetium-99 anti-(α-fetoprotein) Fab' fragment”, J. Cancer Res. Clin. Oncol. (2000) 126:161-167.
Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Ed., Lea & Febiger (1990).
Asano et al., “An Anti-Human VEGF Monoclonal Antibody, MV833, That Exhibits Potent Anti-Tumor Activity in Vivo”, Hybridoma 17(2):185-190 (1998).
Ausubel, F., Current Protocols in Molecular Biology, John Willey & Sons (1987).
Baines et al., “Purification of Immunoglobulin G (IgG)”, Methods in Molecular Biology, vol. 10: Immunochemical Protocols, pp. 79-104, The Humana Press, Inc. (1992).
Barbas et al., “Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen-Specific Fabs”, Methods: A Companion to Methods in Enzymology 2(2):119-124 (1991).
Barnes et al., “Advances in animal cell recombinant protein production:GS-NSO expression system”, Cytotechnology 32:109-123 (2000).
Bei et al., “Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein”, J. Immunol. Methods 186:245-255 (1995).
Bergmann et al., “Radiolabelled monoclonal antibodies against alpha-fetoprotein for in vivo localization of human hepatocellular carcinoma by immunotomoscintigraphy”, Eur. J. Nucl. Med 13:385-390 (1987).
Bird et al., “Single chain antibody variable regions”, Tibtech, vol. 9:132-137 (1991).
Caron et al., “Engineered Humanized Dimeric Forms of IgG are More Effective Antibodies”, J. Exp. Med. 176:1191-1195 (1992).
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy”, Proc. Natl. Acad. Sci. USA 89:4285-4289 (1992).
Co et al., “Chimeric and humanized antibodies with specificity for the CD33 Antigen” J. Immunol. 148(4):1149-1154 (1992).
Coligan et al., (eds.) Current Protocols in Immunology, vol. 1, pp. 2.5.1-2.6.7; 2.7.1-2.7.12; 2.8.1-2.8.10; 2.9.1-2.9.3 and 2.10.-2.10.4, John Wiley & Sons, Inc. (1991).
Colowick et al. (eds.), Methods in Enzymology, vol. I, p. 422, Academic Press Inc. (1955).
Courtenay-Luck, N., “Generic manipulation of monoclonal antibodies”, Monoclonal antibodies: Production, engineering and clinical applicaiton, pp. 166-179, Cambridge University Press (1995).
Colman, A., “Production of therapeutic proteins in the milk of transgenic livestock”, Biochem. Soc. Symp. 63:141-147 (1998).
Coloma et al., “Design and production of novel tetravalent bispecific antibodies”, Nature Biotech. 15:159-163 (1997).
Cragg et al., “Signaling antibodies in cancer therapy”, Curr. Opin. Immunol. 11:541-547 (1999).
Database WPI Week 9121, Derwent Publications Ltd., London, GB, 1991.
Dillman, R., “Antibodies as Cytotoxic Therapy”, J. Clin. Oncol. 12(7):1497-1515 (1994).
Dresel et al., “Detection of Hepatocellular Carcinoma With a new Alpha-Fetoprotein Antibody Imaging Kit”, J. Clin. Oncol. 15(7):2683-2690 (1997).
Edelman et al., “The covalent structure of an entire γG immunoglobulin molecule”, Proc. Natl. Acad. Sci. USA, 63:78-85 (1969).
Fiedler et al., “Optimization of scFv antibody production in transgenic plants”, Immunotechnology 3:205-216 (1997).
Fiedler et al., “High-Level Production and Long-Term Storage of Engineered Antibodies in Transgenic Tobacco Seeds”, Biotechnology 13:1090-1093 (1995).
Fitzgerald et al., “Improved tumour targeting by disulphide stabilized diabodies expressed inPichia pastoris”, Protein Engineering 10(10):1221-1225 (1997).
Gillies et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes”, J. Immunol. Methods, 125:191-202 (1989).
Gennaro, A., Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co. (1990).
Gennaro, A., Remington: The Science and Practice of Pharmacy, 19th ed., vol. I & II, Mack Publishing Co. (1995).
Goodman et al., The Pharmacological Basis of Therapeutics, 7th ed., MacMillan Publishing Co. (1985).
Goldenberg et al., “Cancer Imaging and Therapy with Radiolabeled Antibodies”, Adv. Exp. Med. Biol. 303:107-117 (1991).
Goldenberg et al., “New Developments in Monoclonal Antibodies for Cancer Detection and Therapy”, CA Cancer J. Clin. 44(1):43-64 (1994).
Goldenberg et al., “Monoclonal Antibodies in Cancer Detection and Therapy”, Am. J. Med. 94:297-312 (1993).
Goldenberg et al., “Radiolabeled antibodies as in vivo cancer probes (Review)”, Int. J. Oncol., 3:5-11 (1993).
Goldenberg et al., “The coming of age of cancer radioimmunoconjugates”, Immunol. Today 14(1):5-7 (1993).
Goldenberg et al., “Targeting cancer with radiolabeled antibodies”, Immunol. Today 16(6):261-264 (1995).
Goldenberg et al., “Targeted Therapy of Cancer with Radiolabeled Antibodies”, J. Nucl. Med. 43:693-713 (2002).
Goldenberg et al., “Imaging of Primary and Metastatic Liver Cancer With 131I Monoclonal and Polyclonal Antibodies Against Alphafetoprotein”, J. Clin. Oncol. 5(11):1827-1835 (1987).
Green et al., “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs”, Nature Genetics 7:13-21 (1994).
Greene et al., “Protective Groups in Organic Synthesis”, John Wiley & Sons, Inc. (1999).
Grimm et al., “Mouse α-Fetoprotein-Specific DNA-Based Immunotherapy of Hepatocellular Carcinoma Leads to Tumor Regression in Mice”, Gastroenterology 119(4):1104-1112 (2000).
Hasan et al., “Laser-induced selective cytotoxicity using monoclonal antibody-chromophore conjugates”, Prog. Clin. Biol. Res. 288:471-7 (1989).
Huse, W., “Combinatorial Antibody Expression Libraries in Filamentous Phage”, Antibody Engineering: A Practical Guide, Boerrebaeck (ed.), W.H. Freeman & Co., pp. 103-120 (1992).
Huse at al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda”, Science 246:1275-1281 (1989).
Ishii et al., “Radioimmunodetection of cancer using antibodies to α-fetoprotein and carcinoembryonic antigen”, Annals New York Academy of Sciences 417(1):270-276.
Jackson et al., “Antigen specificity and tumour t
Goldenberg David M.
Hansen Hans J.
Qu Zhengxing
Huff Sheela J
Immunomedics Inc.
Nakashima Richard A.
LandOfFree
Alpha-fetoprotein Immu31 antibodies and fusion proteins and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-fetoprotein Immu31 antibodies and fusion proteins and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-fetoprotein Immu31 antibodies and fusion proteins and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262904